Drugs / mRNA-1273.351
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04785144 | Mar 2021 → Jul 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05289037 | Mar 2022 → Nov 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04405076 | May 2020 → Oct 2021 | Orthocoronavirinae infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2021-08-05 | ModernaTX, Inc. | Results Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates q4web.com ↗
In a Phase 2 study, vaccination with 50 µg of three different Moderna mRNA booster candidates induced robust antibody responses against the wildtype D614G COVID-19 strain and against important variants of concern including Gamma (P.1); Beta (B.1.351); and Delta (B.1.617.2). |
| 2021-05-06 | ModernaTX, Inc. | Results Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates q4web.com ↗ |
| 2021-05-06 | ModernaTX, Inc. | Results Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses q4web.com ↗
mRNA-1273.351, the Company’s strain-matched booster, achieved higher neutralizing antibody titers against the B.1.351 variant of concern than a booster dose of mRNA-1273. |
| 2021-05-05 | ModernaTX, Inc. | Results Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern q4web.com ↗
A booster dose of mRNA-1273.351, the Company’s strain-matched booster, achieved higher neutralizing antibody titers against the B.1.351 variant of concern than a booster dose of mRNA-1273. |
| 2021-04-13 | ModernaTX, Inc. | Results Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day q4web.com ↗
New results from a preclinical study of the Company’s COVID-19 variant-specific vaccine candidates showed that the Company’s variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-08-05 | ModernaTX, Inc. | Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates q4web.com ↗ |
| 2021-05-06 | ModernaTX, Inc. | Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates q4web.com ↗ |
| 2021-05-06 | ModernaTX, Inc. | Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses q4web.com ↗ |
| 2021-05-05 | ModernaTX, Inc. | Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern q4web.com ↗ |
| 2021-04-13 | ModernaTX, Inc. | Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day q4web.com ↗ |
| 2021-02-24 | ModernaTX, Inc. | Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study q4web.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1273.351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05289037 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-1273.351 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine” NCT04785144 ↗ |
| Route | Intramuscular | “1 IM booster dose of 20 ug of mRNA 1273.351 on Day 1” NCT04405076 ↗ |